High levels of endorphin and related pathologies of veterinary concern. A review.
The authors report information about endogenous opioid peptides (EOP), receptors, antagonists and their interference with pain, stress, endocrine and immune system. A relationship between EOP and calcium homeostasis, both at extracellular and intracellular level, has been observed. In vitro, beta-endorphin exerts different actions through calcium channel functionality in epithelial cells. In rat aorta and cerebral cortex: beta-endorphin or Naloxone alternatively influence oocyte maturation through the mu-receptor gene expression and intracellular calcium concentration in granulosa and cumulus cells. Calcium channel block is removed by administrating Naloxone and calcium. In vivo, Naloxone and calcium removes EOP induced apoptosis in granulosa cells; is the most safe therapy in cow's milk fever; allow to remove ovarian follicular cysts. A negative influence of opioids on immune response after vaccination was established; EOP-related metabolic problems in post-partum cows. Abnormal intestinal motility, in which a Ca++ influence is well known, can be removed by Naloxone and calcium administration. Calcium-related function and neuromodulation must be re-evaluated since high level of EOP are involved in many pathologies through their influence on calcium activity. The use of calcium salts and Naloxone offers a safe and supplementary therapeutical possibility, active in any condition of altered endogenous opioids.
Sciorsci
R L
RL
Department of Veterinary and Agro-Alimentary Sciences, Veterinary Medicine, University of Teramo, Italy.
Bianchi
P
P
Minoia
P
P
D000820:Animal Diseases / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D005075:Biological Evolution; D020013:Calcium Signaling; D004723:Endorphins / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D006728:Hormones / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D018847:Opioid Peptides / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D010146:Pain / Q000503:physiopathology; D051381:Rats; D011957:Receptors, Opioid / Q000378:metabolism; D013312:Stress, Physiological / Q000378:metabolism
D004723:Endorphins; D006728:Hormones; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D011957:Receptors, Opioid; D009270:Naloxone; D019204:GTP-Binding Proteins